Neurology | Preclinical Developments | UNITED STATES

AxoProtego Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

AxoProtego Therapeutics Announces Novel Investigational Agent for Chemotherapy-Induced Peripheral Neuropathy

Lead Product(s): EQ-6

Therapeutic Area: Neurology Product Name: EQ-6

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 27, 2020

Details:

AxoProtego has licensed the rights for the worldwide development and commercialization of Ethoxyquin and its derivatives (including EQ-6, its lead compound) from The Johns Hopkins University.

Tonix Pharmaceuticals Holding Corp

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Tonix Pharma Announces that Preclinical Study of TNX-1900 Will be Presented in a Poster at the AAN Sports Concussion Meeting

Lead Product(s): Oxytocin

Therapeutic Area: Neurology Product Name: TNX-1900

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 27, 2020

Details:

Preclinical results of TNX-1900 (oxytocin solution for intranasal delivery) will be presented in a poster at the American Academy of Neurology’s first-ever Sports Concussion Conference.

Encoded Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Encoded Therapeutics Announces $135 Million Series D Financing to Support First Clinical Trials in SCN1A+ Dravet Syndrome

Lead Product(s): ETX101

Therapeutic Area: Neurology Product Name: ETX101

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: GV

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Series D Financing July 22, 2020

Details:

ETX101, Encoded's lead asset, was granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation by FDA for the treatment of SCN1A+ Dravet Syndrome.

Knopp Biosciences LLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Knopp Biosciences Receives Rare Pediatric Disease Designation for Kv7 Activator KB-3061 for Treatment of KCNQ2 Epileptic Encephalopathy

Lead Product(s): KB-3061

Therapeutic Area: Neurology Product Name: KB-3061

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 15, 2020

Details:

Knopp is advancing the development of KB-3061 as a potential precision medicine for KCNQ2-EE, a rare genetic disease associated with seizures beginning in the first days of life and profound neurodevelopmental delay.

Tranquis Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Tranquis Therapeutics Launches with $30 Million Series A Funding to Advance Novel Immuno-Neurology to Treating Neurodegenerative Diseases

Lead Product(s): TQS-168

Therapeutic Area: Neurology Product Name: TQS-168

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Remiges Ventures

Deal Size: $30.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing July 09, 2020

Details:

The financing will support company's novel platform based on groundbreaking research from the laboratory of Professor Edgar Engleman, MD, at Stanford University indicating that myeloid immune cell dysfunction underlies a variety of nervous system disorders.

QurAlis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

2 Months After Launch, QurAlis Nabs Early ALS Compounds from Eli Lilly

Lead Product(s): Undisclosed

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Eli Lilly

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 01, 2020

Details:

Company has penned a preclinical pact with Eli Lilly to deepen its ALS pipeline, in-licensing an undisclosed number of preclinical compounds with “disease modifying potential” in ALS by preventing disease-induced neuronal excitotoxicity.

Seelos Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-007 in Parkinson's Disease

Lead Product(s): SLS-007

Therapeutic Area: Neurology Product Name: SLS-007

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 25, 2020

Details:

Seelos has initiated an in vivo preclinical study of SLS-007 in rodents to assess the ability of two specific novel peptides, S62 and S71, delivered via AAV1/2 viral vector, to protect dopaminergic function in the preformed α-synuclein fibril (PFF) rodent model of PD.

Yumanity Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Yumanity Therapeutics Signs Drug Development Deal with Merck

Lead Product(s): Undisclosed

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Merck & Co. Inc.

Deal Size: $500.0 million Upfront Cash: Undisclosed

Deal Type: Agreement June 24, 2020

Details:

Under the terms of the agreement, Merck will gain exclusive rights to two novel Yumanity pipeline programs for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD).

Greene Street Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

VerdePharmHealth Signs Exclusive Partnership Agreement with Greene Street Pharmaceuticals for Cannabidiol Transdermal Patch

Lead Product(s): Cannabidiol

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: VerdePharmHealth

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership June 10, 2020

Details:

Collaboration will utilize proprietary CBD-Cubed™ transdermal 24-hour delivery technology for multi-specialty patients.

Seelos Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-004 in Parkinson’s Disease

Lead Product(s): SLS-004

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 28, 2020

Details:

Company to initiate preclinical study of SLS-004 in Parkinson’s disease (PD) through an all-in-one lentiviral vector targeting the synuclein alpha (SNCA) gene.

Find

Find Novel Neurology Drugs in Preclinical Development in UNITED STATES

United States

Product Type

Companies

AxoProtego Therapeutics

AxoProtego Therapeutics Announces Novel Investigational Agent for Chemotherapy-Induced Peripheral Neuropathy

Tonix Pharmaceuticals Holding Corp

Tonix Pharma Announces that Preclinical Study of TNX-1900 Will be Presented in a Poster at the AAN Sports Concussion Meeting

Encoded Therapeutics

Encoded Therapeutics Announces $135 Million Series D Financing to Support First Clinical Trials in SCN1A+ Dravet Syndrome

Knopp Biosciences LLC

Knopp Biosciences Receives Rare Pediatric Disease Designation for Kv7 Activator KB-3061 for Treatment of KCNQ2 Epileptic Encephalopathy

Tranquis Therapeutics

Tranquis Therapeutics Launches with $30 Million Series A Funding to Advance Novel Immuno-Neurology to Treating Neurodegenerative Diseases

QurAlis

2 Months After Launch, QurAlis Nabs Early ALS Compounds from Eli Lilly

Seelos Therapeutics

Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-007 in Parkinson's Disease

Yumanity Therapeutics

Yumanity Therapeutics Signs Drug Development Deal with Merck

Greene Street Pharmaceuticals

VerdePharmHealth Signs Exclusive Partnership Agreement with Greene Street Pharmaceuticals for Cannabidiol Transdermal Patch

Seelos Therapeutics

Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-004 in Parkinson’s Disease